Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

Affiches Mar 3, 2026

Oncologie

Spectrométrie de masse

March 3, 2026

Luca Genovesi, Laurence Mayrand Provencher, Nick Dupuis, Gwenael Pottiez

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

Affiches

Apr 14, 2026

Understanding Protein Normalization: A Case Study in PBMC Fit-for-Purpose Validation by MS

Affiches

Mar 3, 2026

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

Poster: microsampling with intact-mass HRMS for M-protein monitoring and MRD in myeloma.

Affiches

Nov 10, 2025

Can Microsampling Devices Coupled with Intact Mass High-Resolution Mass Spectrometry Improve M-Protein Monitoring and Simplify Minimal Residual Disease Assessment in Multiple Myeloma?

CellCarta has the multi-modal capabilities, scientific depth, and harmonized global footprint needed to advance even the most complex programs in precision medicine.

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

Featured Resources

Understanding Protein Normalization: A Case Study in PBMC Fit-for-Purpose Validation by MS

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

Can Microsampling Devices Coupled with Intact Mass High-Resolution Mass Spectrometry Improve M-Protein Monitoring and Simplify Minimal Residual Disease Assessment in Multiple Myeloma?

One global CRO for your whole therapeutic development journey